Some of the distinctive characteristics of oral medication administration, such as its affordable therapeutic costs, convenience of use, improved patient acceptance and compliance, and a wide variety of dose forms, have contributed to its rise in popularity.

Despite some variation, the oral drug administration method has a number of drawbacks when it comes to getting the medication into the upper gastrointestinal tract¹. Development of oral controlled release dosage forms that can provide the medication for an extended amount of time at a predefined pace². One of the many strategies that are most likely used to extend the gastric residence durations (GRT) is floating drug delivery systems (FDDS)³.

The theory behind floating systems, which Davis discovered in 1968, is that because they are less dense and have a higher buoyancy to float above the gastric juices in the stomach and support prolonged activity⁴. Floating drug delivery systems can prolong the half-life of short-lived biological pharmaceuticals, enhancing their effectiveness and reducing the need for frequent dosage⁵. In addition to helping to improve absorption, floating drugs delivery methods strike to extend the dosage form's time in the gastrointestinal tract. Specifically, these mechanisms are better adapted to drugs with a specific absorption location in the upper region of the small intestine and greater solubility in acidic environments .Certain drugs—namely, those that operate locally in the stomach, are absorbed exclusively there, have a limited window of absorption, are poorly soluble at an alkaline pH, and are unstable in the intestinal or colonic environment—are particularly interesting candidates for floating drug delivery⁶.

Particularly intriguing candidates for floating drug delivery include some medications that act locally in the stomach, are only absorbed there, have a small window of absorption, are poorly soluble at alkaline pH, and are unstable in the intestinal or colonic environment⁷. FDDS, a class of gastro-retentive drug delivery systems, is a relatively recent advancement in pharmaceutical technology that provides several advantages over conventional drug administration methods⁸. They are recognized as an essential instrument for achieving adequate stomach retention and pharmaceutical absorption⁹. FDDS are sufficiently buoyant to float over the stomach's contents and remain there for a considerable length of time¹⁰. long time without reducing the stomach's pace of emptying¹¹.

· Floating drug delivery systems help overcome the problem of rapid gastrointestinal transit time, which often limits the bioavailability of conventional oral dosage forms¹².

· FDDS are especially useful for drugs with a short biological half-life, ensuring sustained therapeutic action¹³.

· The system aligns with the concept of personalized medicine, as it allows tailoring drug release profiles to patient needs¹⁴.

OBJECTIVES OF FDDS:

1) To provide an overview of the concept and mechanism of Floating Drug Delivery Systems

2) To discuss the need and advantages of FDDS compared to conventional oral drug delivery systems.

3) To highlight the formulation components and classification of FDDS.

4) To identify suitable and unsuitable drug candidates for floating drug delivery.

5) To explore the factors affecting the performance and efficiency of FDDS.

6) To summarize the therapeutic applications of FDDS in various diseases.

7) To analyze recent advancements and future perspectives in FDDS, including nanotechnology, smart polymers, and 3D printing approaches.

NEED FOR FLOATING DRUG DELIVERY SYSTEMS:

The pharmaceutical sector commonly treats ailments with traditional oral administration, which highlights the need for floating drug delivery systems¹⁵. Non-site specificity is the primary issue with traditional distribution, while there are other issues as well¹⁶.

· Some drugs only absorb where they are supposed to. They insist on a release at a predetermined point or one that guarantees the greatest amount of medication gets to the desired spot.¹⁷

· These drugs that must be site-specific are presently the focus of the pharmaceutical industry¹⁸. Gastro-retentive delivery is one site-specific technique for getting drugs into the stomach or intestines¹⁹.

· The drug is given by holding the dose form in the stomach and releasing it gradually at a predetermined position into the duodenum, intestine, or stomach²⁰.

· Improves the bioavailability of drugs that are otherwise incompletely absorbed due to short residence in the stomach²¹.

· Reduces dose dumping and maintains steady plasma concentration for extended durations²².

· Provides localized delivery for treating gastric disorders (ulcers, gastritis, H. pylori infections)²³.

· Decreases the frequency of administration, improving patient compliance²⁴.

Floating Drug Delivery System (FDDS) Components :

The following elements are included in the FDDS formulation:

Hydrocolloids	Polymers	Effervescent Agent
Buoyancy Increasing Agent	Low-density materials	Gas-forming agents

Inert Fatty Materials	Release Rate Modifier	Release Rate Modifier
Bioadhesive polymers	Super-porous hydrogels	Miscellaneous

● Hydrocolloids: These are artificial, slightly altered cellulose derivatives that can be either anionic or nonionic, such as bentonite, agar, pectin, gelatin, and acacia²⁵.

● Polymers: The development of floating drug delivery mostly uses polymers such as HPMC K4M, HPMC K15M, HPMC K100M, polyethylene glycol, polycarbonate, sodium alginate, PVA, PVP, eudragit, carbopol, methyl methacrylate, and acrylic polymers²⁶.

● Effervescent Agent: To create effervescent-based floating formulations, effervescent agents such as sodium bicarbonate, citric acid, tartaric acid, nitroglycerin, and di-sodium glycine carbonate are utilized²⁷.

● Inert Fatty Materials: By having a specific gravity below one, fatty materials lose their hydrophilic qualities and enhance buoyancy.E.g. Beeswax, fatty acid, long-chain alcohol, mineral oil²⁸.

● Release Rate Modifier: Excipients such as lactose and mannitol can be used to alter the formulation's release rate²⁹.

● Release Rate Retardants: They slow the release of medications by decreasing their solubility. For instance, magnesium stearate, talc, and dicalcium phosphate³⁰.

● Buoyancy Increasing Agent: Ethyl cellulose and other materials with a low bulk density (less than one) can be employed to make the formulation more buoyant. It might account for 80% of the weight³¹.

● Low-density materials: such as powdered polypropylene foam, are utilized when it's required to reduce the formulation's weight so that it can float³².

● Miscellaneous: Depending on the needs, the formulation may include adjuvants such as binders, lubricants, stabilizers, and preservatives³³.

● Gas-forming agents :(e.g., sodium bicarbonate + citric acid) are crucial in effervescent systems for generating carbon dioxide, which imparts buoyancy³⁴.

● Bioadhesive polymers: can be used to increase gastric retention in combination with floating systems³⁵.

● Super-porous hydrogels :are emerging as excipients because of their fast swelling and excellent floatability³⁶.

Suitable Drug Candidates for FDDS	Unsuitable Drug Candidates for FDDS
Drugs with a narrow absorption window in the upper GIT (e.g., Theophylline, L-DOPA, Methotrexate)	Drugs with limited solubility in acidic media (e.g., Phenylhydantoin, Phenytoin)⁴⁰
Drugs that act locally in the stomach (e.g., Anti-ulcer drugs, Misoprostol, Antacids)	Drugs unstable in the gastric environment (e.g., Erythromycin)⁴¹
Drugs unstable or degraded in the intestinal/colonic environment (e.g., Metformin HCl, Ranitidine HCl, Captopril, Metronidazole)³⁷	Drugs intended for selective colon release (e.g., Corticosteroids, Mesalamine, 5-Amino salicylic acid)⁴²
Drugs that target gastric pathogens or disturb colonic microflora (e.g., Tetracycline, Clarithromycin, Amoxicillin for H. pylori eradication)³⁸	Drugs with absorption not dependent on gastric retention (not benefitted by FDDS)
Drugs poorly soluble at higher pH levels (e.g., Furosemide, Diazepam, Chlordiazepoxide, Verapamil HCl)³⁹	Drugs requiring immediate release for therapeutic action (not suitable for sustained floating systems)

Floating Drug Delivery System:

The floating drug delivery system's bulk thickness is smaller than that of GI fluid, it can stay afloat in the abdomen for longer periods of time without affecting the stomach's natural emptying process⁴³. The material floats during this process and is expelled from the body at a critical pace after the medication is released⁴⁴. This raises the possibility that bacteria will infiltrate the body and makes controlling the quantities of bacterial drugs easier⁴⁵.

Fig No.1 Internal structrure of GI Tract

Fig.No.2 Gastro Intestinal Tract

The Floating Medication Delivery System's Mechanism:

Because the bulk density is lower than that of gastric fluids, floating drug delivery systems (FDDS) float in the stomach for extended periods of time without slowing down the rate of gastric emptying.⁴⁶ As can be seen in Figure No. 3, the medication is released from the body at the proper rate while the system is floating on the contents of the stomach⁴⁷. However, in addition to the minimal stomach content required to meet the buoyancy retention principle, a minimal amount of floating force (F) is also required to maintain the dose form's consistent buoyancy on the meal's surface⁴⁸. A particular technique for determining resultant weight has been developed in the literature to assess the dynamics of the floating force⁴⁹.

While the system is floating on the contents of the stomach, the drug is released from the body at the appropriate pace⁵⁰. However, to maintain the dosage form's constant buoyancy on the surface of the meal, a little amount of floating force (F) is also needed, in addition to the minimum stomach content needed to satisfy the buoyancy retention principle. In order to evaluate the dynamics of the floating force, a specific method for calculating resultant weight has been devised in the literature.

F = F buoyancy – F gravity = (Df – Ds) gv⁵¹

Where,

F = total vertical force,

Df = fluid density,

Ds = object density,

v = volume,

g = acceleration due to gravity

Fig No 3: Floating and High Density System

Mechanism of Floating Drug Delivery System

Non-effervescent systems rely

on swelling polymers and gel-forming agents

that entrap air and reduce density.

Effervescent systems generate gas (CO₂) that gets trapped in the gel matrix,

allowing the dosage form to float.

Dual-mechanism systems combine both strategies for more reliable buoyancy.⁵²

Advantages of FDDS:

§ Sustained drug release with improved absorption⁵³.

§ Reduces side effects by maintaining controlled plasma drug levels⁵⁴.

§ Targets specific regions of the stomach and upper intestine.⁵⁵

Limitations of FDDS:

o Not suitable for drugs with very high dose requirements.⁵⁶

o Floating may fail in patients with gastrointestinal motility disorders⁵⁷.

o Requires sufficient gastric fluid for buoyancy⁵⁸.

o Unsuitable for drugs that cause gastric irritation.⁵⁹

Recent Advances in FDDS:

I. Development of floating microspheres/nanospheres for better control of drug release:⁶⁰

§ These are hollow particles that remain buoyant in gastric fluids.

§ Their small size provides a large surface area, leading to more uniform and controlled drug release.

§ They are especially useful for drugs with a short half-life or narrow absorption window, improving bioavailability.

II. Raft-forming systems for treating GERD and reflux disorders:⁶¹

§ These systems form a viscous, gel-like “raft” layer that floats on gastric contents after contact with gastric fluid.

§ Mainly applied in the treatment of gastroesophageal reflux disease (GERD)** and other reflux disorders.

§ The raft acts as a physical barrier, preventing reflux and prolonging gastric retention.

III. Use of 3D printing technology for personalized floating tablets⁶².

§ 3D printing allows precise design of tablet geometry and density, ensuring floating capability.

§ Enables personalized medicine, where dose, release profile, and floating behavior can be tailored to the patient’s needs.

§ Improves therapeutic outcomes and patient compliance.

IV. Combination systems: Floating+mucoadhesive, floating + expandable⁶³.

§ Floating+Mucoadhesive systems** combine buoyancy with adhesion to the gastric mucosa, ensuring prolonged gastric residence.

§ Floating+Expandable systems** swell to a larger size in the stomach, preventing premature passage into the intestine.

§ Both approaches enhance drug retention time and improve absorption efficiency

Classification of Floating Drug Delivery Systems (FDDS)

I. Effervescent systems: Gas-generating agents (sodium bicarbonate + citric/tartaric acid) create CO₂, which helps floatation⁶⁴.

II. Non-effervescent systems: Use polymers (HPMC, PVA, PVP) that swell and form a gel barrier, entrapping air and reducing density.

III. Raft-forming systems: Form viscous cohesive gels that float on gastric fluids (used in antacids/GERD treatment).

IV. Hydrodynamically balanced systems (HBS): Capsules filled with drugs + hydrocolloids, forming low-density gels.

V. Multi-unit floating systems: Floating microspheres or beads reduce risk of dose-dumping and provide uniform drug release.⁶⁵

Factors Affecting FDDS Performance:

· Gastric pH and motility (fasted vs. fed state strongly influences retention).

· Density of formulation (must be < 1.004 g/cm³ to float).

· Size and shape of dosage form (larger tablets tend to have longer retention).

· Viscosity and concentration of polymers used.

· Food intake (fatty meals delay gastric emptying, enhancing FDDS retention).⁶⁶

Applications of FDDS:

i. Peptic ulcer therapy: Sustained release of anti-ulcer drugs (famotidine, ranitidine).

ii. Helicobacter pylori eradication: Floating antibiotics like amoxicillin, tetracycline, clarithromycin.

iii. Antihypertensive therapy: Controlled release of captopril, verapamil.

iv. Antidiabetic therapy: Floating metformin HCl formulations to enhance bioavailability.

v. Pain management: Prolonged delivery of NSAIDs to minimize gastric irritation.⁶⁷

Future Perspectives:

· Integration of nanotechnology with FDDS for targeted drug delivery.⁶⁸

· Smart polymers that respond to pH or temperature changes to optimize drug release.⁶⁹

· 3D-printed floating systems for personalized medicine⁷⁰.

· Combining floating + pulsatile delivery for chronotherapy of diseases (like hypertension or asthma).⁷¹

CONCLUSION:

Floating drug delivery systems represent a significant advancement in oral controlled drug delivery, improving bioavailability and therapeutic efficacy of drugs with narrow absorption windows. Despite certain limitations, ongoing innovations in formulation strategies make FDDS a promising platform for achieving sustained, site-specific, and patient-friendly drug therapy.

REFERANCES:

1. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clinical Pharmacokinetics. 2002 Aug; 41(9):661-80.

2. Gupta PK, Robinson JR. Oral controlled-release delivery. Treatise on Controlled Drug Delivery. 2017 Oct 2: 255-313.

3. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. Drug Delivery. 2011 Feb 1; 18(2): 97-110.

4. Kamini KM, Pooni N, Singh M, Verma K, Dhiman N, Sharma N, Bhandari N. Floating Drug Delivery System:-A Review. WJ Pharm. P’ceutical. Sci. 2017. 2017 Jan 30; 6(4): 578-94.

5. Bhardwaj V, Harikumar SL. Floating drug delivery system: A review. Pharmacophore. 2013; 4(1-2013): 26-38.

6. Raikwar S, Jain SK. Gastrointestinal absorption of drugs. InPhysico-Chemical Aspects of Dosage Forms and Biopharmaceutics 2024 Jan 1 (pp. 147-164). Academic Press.

7. Reddy LH, Murthy RS. Floating dosage systems in drug delivery. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2002; 19(6).

8. Das S, Kaur S, Rai VK. Gastro-retentive drug delivery systems: A recent update on clinical pertinence and drug delivery. Drug Delivery and Translational Research. 2021 Oct; 11(5): 1849-77.

9. Davis SS. Formulation strategies for absorption windows. Drug discovery today. 2005 Feb 15; 10(4): 249-57.

10. Rajendra BA, SJ V, CR S. A comprehensive review on floating drug delivery system (FDDS). Res J Pharm Biol Chem Sci. 2020; 10(6): 174-82

11. .Hellström PM, Grybäck P, Jacobsson H. The physiology of gastric emptying. Best Practice & Research Clinical Anaesthesiology. 2006 Sep 1; 20(3): 397-407.

12. Sharma N, Agarwal D, Gupta MK, Khinchi M. A comprehensive review on floating drug delivery system. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011 Apr; 2(2): 428-41.

13. Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, Chowdhury EH. Current strategies in extending half-lives of therapeutic proteins. Journal of Controlled Release. 2019 May 10; 301: 176-89

14. Geraili A, Xing M, Mequanint K. Design and fabrication of drug‐delivery systems toward adjustable release profiles for personalized treatment. View. 2021 Oct; 2(5): 20200126..

15. Dixit N. Floating drug delivery system. Journal of Current Pharmaceutical Research. 2011; 7(1): 6-20.

16. Foody GM. Latent class modeling for site-and non-site-specific classification accuracy assessment without ground data. IEEE Transactions on Geoscience and Remote Sensing. 2011 Dec 19; 50(7): 2827-38.

17. Mayersohn M. Principles of drug absorption. InModern Pharmaceutics Volume 1 2009 May 28 (pp. 41-98). CRC Press.

18. Pandey A, Mishra S, Tiwari A, Misra K. Targeted drug delivery (Site specific drug delivery). Journal of Scientific and Industrial Research. 2004 Mar 1; 63(3): 230-47.

19. Shah K, Singh D, Agrawal R, Garg A. Current developments in the delivery of gastro-retentive drugs. AAPS PharmSciTech. 2025 Feb 7; 26(2): 57.

20. Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Development and Industrial Pharmacy. 1996 Jan 1; 22(6): 531-9.

21. Sim DS. Drug absorption and bioavailability. InPharmacological basis of acute care 2014 Oct 7 (pp. 17-26). Cham: Springer International Publishing.

22. Holford NH. Pharmacokinetics & Pharmacodynamics: rational dosing and the time course of drug action. Basic & Clinical Pharmacology. 2009; 13.

23. Gupta A, Shetty S, Mutalik S, Mathew EM, Jha A, Mishra B, Rajpurohit S, Ravi G, Saha M, Moorkoth S. Treatment of H. pylori infection and gastric ulcer: Need for novel Pharmaceutical formulation. Heliyon. 2023 Oct 1; 9(10).

24. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997 Oct 1; 20(10):1512-7.

25. Wüstenberg T. General overview of food hydrocolloids. Cellulose and Cellulose Derivatives in the Food industry Fundamentals and Applications; Wüstenberg, T., Ed. 2015:1-68.

26. Iglesias N, Galbis E, Romero-Azogil L, Benito E, Lucas R, García-Martín MG, de-Paz MV. In-depth study into polymeric materials in low-density gastroretentive formulations. Pharmaceutics. 2020 Jul 7; 12(7):636.

27. Ali MN, Malek A, Akter P, Al Juhan A, Safrin F, Akter F. A Comprehensive Review on Floating Drug Delivery System. Saudi J Med Pharm Sci. 2025; 11(5):383-93.

28. Gunda RK, Vijayalakshmi A. Formulation development and evaluation of gastro retentive drug delivery systems-a review. J Pharm Res. 2017 Feb 27; 11:167-78.

29. Ohrem HL, Schornick E, Kalivoda A, Ognibene R. Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms?. Pharmaceutical Development and Technology. 2014 May 1; 19(3): 257-62.

30. McGinity JW, O'Donnell PB. Pharmaceuticals. InIndustrial Minerals and Their Uses 1996 Jan 1 (pp. 401-433). William Andrew Publishing.

31. Ishak RA. Buoyancy-generating agents for stomach-specific drug delivery: an overview with special emphasis on floating behavior. Journal of Pharmacy & Pharmaceutical Sciences. 2015 Mar 9; 18(1): 77-100.

32. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. International Journal of Pharmaceutics. 2002 Jul 25; 241(2): 279-92.

33. Green JM, Beestman GB. Recently patented and commercialized formulation and adjuvant technology. Crop Protection. 2007 Mar 1; 26(3): 320-7.

34. Ishak RA. Buoyancy-generating agents for stomach-specific drug delivery: an overview with special emphasis on floating behavior. Journal of Pharmacy & Pharmaceutical Sciences. 2015 Mar 9; 18(1):77-100.

35. Naseem F, Shah SU, Rashid SA, Farid A, Almehmadi M, Alghamdi S. Metronidazole based floating bioadhesive drug delivery system for potential eradication of H. pylori: preparation and in vitro characterization. Polymers. 2022 Jan 27; 14(3): 519.

36. Kumari PK, Sharmila M, Rao YS. Super porous hydrogels: a review. J. Pharm. Res. Int. 2020; 32: 153-65.

37. Domagała-Rodacka R, Cibor D, Szczeklik K, Rodacki T, Mach T, Owczarek D. Gastrointestinal tract as a side-effect target of medications.

38. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug 1; 59(8): 1143-53.

39. APRD00642 D, Renal E, S4 PO, Schedule IV CA IV S, Schedule IV. Physical properties.

40. Schwartz PA, Rhodes CT, Cooper Jr JW. Solubility and ionization characteristics of phenytoin. Journal of Pharmaceutical Sciences. 1977 Jul; 66(7):994-7.

41. Czarnetzki C, Elia N, Frossard JL, Giostra E, Spahr L, Waeber JL, Pavlovic G, Lysakowski C, Tramèr MR. Erythromycin for gastric emptying in patients undergoing general anesthesia for emergency surgery: a randomized clinical trial. JAMA Surgery. 2015 Aug 1; 150(8): 730-7.

42. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003 Jan 1; 6(1):33-66.

43. Gupta RK, Panda P, Kumar D. An Overview On The Analysis Of The Floating Drug Delivery System. World Journal of Pharmaceutical Research. 2024 Apr 16; 13(11):708-24.

44. Madhavi N. Comprehensive Review on Gastro Retentive Drug Delivery System.

45. Yeh YC, Huang TH, Yang SC, Chen CC, Fang JY. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Frontiers in Chemistry. 2020 Apr 24; 8: 286.

46. Vasave VS. A review on: floating drug delivery system. World J Pharmaceut Res. 2023; 12(2): 641-69.

47. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharmaceutical Research. 1993 Sep; 10(9): 1321-5.

48. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2003; 20(6).

49. Singh P, Joseph DD. Fluid dynamics of floating particles. Journal of Fluid Mechanics. 2005 May; 530:31-80.

50. Kotreka U, Adeyeye MC. Gastroretentive floating drug-delivery systems: a critical review. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2011; 28(1).

51. Rosensweig RE. Fluidmagnetic buoyancy. Aiaa Journal. 1966 Oct; 4(10): 1751-8.

52. Sreekanth Y. Formulation and Evaluation of Nizatiding Floatince Table (Doctoral dissertation, KK College of Pharmacy, Chennai).

53. Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Advanced Drug Delivery Reviews. 2014 Aug 30; 75:81-91.

54. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, Vella S, Bassetti D. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic Drug Monitoring. Aids. 1999 Oct 22; 13(15): 2083-9.

55. Treuting PM, Arends MJ, Dintzis SM. Upper gastrointestinal tract. InComparative Anatomy and Histology 2018 Jan 1 (pp. 191-211). Academic Press.

56. Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nature reviews Clinical oncology. 2014 May; 11(5): 272-81.

57. Shin A. Disorders of gastric motility. The Lancet Gastroenterology & Hepatology. 2024 Nov 1; 9(11):1052- 64.

58. Timmermans J, Moës AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. Journal of Pharmaceutical Sciences. 1994 Jan; 83(1): 18-24

59. McQuaid KR. Drugs used in the treatment of gastrointestinal diseases. Basic & Clinical Pharmacology. 2018; 12..

60. Singh LD, Ganju DK, Amit B. Floating microsphere as novel approach drug delivery system. Asian Journal of Science and Technology. 2019 Sep; 10(09): 10103-12.

61. Niranjanbhai BD, Mahendrakumar VN, Surendran CS, Viral S, Upadhyay UM. Advances in grdds: raft forming system a review. Journal of Drug Delivery & Therapeutics. 2012; 2(5): 123-8.

62. Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, Molina G, Diez L, Ramirez BI, Ramirez IO, Sánchez-Guirales SA. 3D printing technologies in personalized medicine, nanomedicines, and biopharmaceuticals. Pharmaceutics. 2023 Jan 17; 15(2): 313.

63. Naseem F, Shah SU, Rashid SA, Farid A, Almehmadi M, Alghamdi S. Metronidazole based floating bioadhesive drug delivery system for potential eradication of H. pylori: preparation and in vitro characterization. Polymers. 2022 Jan 27; 14(3): 519.

64. Alburyhi MM, Moharram BA. Formulation and Evaluation Of Aloe Niebuhriana Extract As Naturaceutical Effervescent Granules Novel Drug Delivery Systems For Antidiabetic Activity.

65. Başarır NS, Mesut B, Özsoy Y. A review on current perspective of gastroretentive drug delivery systems prioritising floating dosage forms. Sağlık Bilimlerinde İleri Araştırmalar Dergisi. 2021; 4(2): 43-64.

66. Shelar SN. Development and evaluation of floating microspheres of ketoprofen (Master's thesis, Rajiv Gandhi University of Health Sciences (India)).

67. Garg T, Kumar A, Rath G, Goyal A. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2014; 31(6).

68. Rao NR, Sheela MA, Maurya MA, Ali MI. Molecular pharmaceutics (nano technology & targeted dds). Jec publication; .

69. Biomaterials Science, Polymer Edition. 2008 Jan 1; 19(6): 755-67.

70. Alzoubi L, Aljabali AA, Tambuwala MM. Empowering precision medicine: the impact of 3D printing on personalized therapeutic. Aaps Pharmscitech. 2023 Nov 14; 24(8): 228.

71. Vaniprasanna T, Traitel T, Goldbart R, Kost J. Smart polymers for responsive drug-delivery systems. Journal of Murthy TG, Rao AS. An Over View of Chronotherapeutic Drug Delivery Systems Based on Floating Pulsatile Concept. Drugs. 3:4.

Received on 23.10.2025 Revised on 13.11.2025

Accepted on 29.11.2025 Published on 20.01.2026

Available online from January 27, 2026

Asian J. Pharm. Tech. 2026; 16(1):99-104.

DOI: 10.52711/2231-5713.2026.00014

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.